Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Rockwell Medical (RMTI) Gains from Sales and Divestitures (2018 - 2019)

Rockwell Medical's Gains from Sales and Divestitures history spans 2 years, with the latest figure at $96542.0 for Q3 2019.

For Q3 2019, Gains from Sales and Divestitures changed N/A year-over-year to $96542.0; the TTM value through Sep 2019 reached $96542.0, changed N/A, while the annual FY2018 figure was $98500.0, N/A changed from the prior year.
Gains from Sales and Divestitures reached $96542.0 in Q3 2019 per RMTI's latest filing, down from $98500.0 in the prior quarter.
In the past five years, Gains from Sales and Divestitures ranged from a high of $98500.0 in Q4 2018 to a low of $96542.0 in Q3 2019.